TY - JOUR
T1 - B-cell immune repertoire sequencing in tobacco cigarette smoking, vaping, and chronic obstructive pulmonary disease in the COPDGene cohort
AU - Moll, Matthew
AU - Xu, Zhonghui
AU - Boueiz, Adel
AU - Ryu, Min Hyung
AU - Silverman, Edwin K.
AU - Cho, Michael H.
AU - Hersh, Craig P.
AU - Sauler, Maor
AU - Polverino, Francesca
AU - Kinney, Gregory L.
AU - Curtis, Jeffrey L.
AU - Crotty-Alexander, Laura E.
AU - Vollmers, Christopher
AU - Castaldi, Peter J.
N1 - Publisher Copyright:
Copyright © 2025 Moll, Xu, Boueiz, Ryu, Silverman, Cho, Hersh, Sauler, Polverino, Kinney, Curtis, Crotty-Alexander, Vollmers and Castaldi.
PY - 2025
Y1 - 2025
N2 - Rationale: Cigarette smoking (CS) impairs B-cell function and antibody production, increasing infection risk. The impact of e-cigarette use ('vaping') and combined CS and vaping ('dual-use') on B-cell activity is unclear. Objective: To examine B-cell receptor sequencing (BCR-seq) profiles associated with CS, vaping, and dual-use. Methods: BCR-seq was performed on blood RNA samples from 234 participants in the COPDGene study. We assessed multivariable associations of B-cell function measures (immunoglobulin heavy chain (IGH) subclass expression and usage, class-switching, V allele usage, and clonal expansion) with CS, vaping, and dual-use. We adjusted for multiple comparisons using the Benjamini-Hochberg method, identifying significant associations at 5% FDR and suggestive associations at 10% FDR. Results: Among 234 non-Hispanic white (NHW) and African American (AA) participants, CS and dual-use were significantly positively associated with increased secretory IgA production, with dual-use showing the strongest associations. Dual-use was positively associated with class switching and B-cell clonal expansion, indicating increased B-cell activation, with similar trends in those only smoking or only vaping. The IGHV5-51*01 allele was increased in dual users. Conclusions: CS and vaping additively enhance B-cell activation, most notably in dual-users. CS and vaping are significantly associated to multiple alterations in B-cell function including increased class switching, clonal expansion, and a shift towards IgA-producing cell populations. These changes could be relevant to response to infection and vaccinations and merit further study.
AB - Rationale: Cigarette smoking (CS) impairs B-cell function and antibody production, increasing infection risk. The impact of e-cigarette use ('vaping') and combined CS and vaping ('dual-use') on B-cell activity is unclear. Objective: To examine B-cell receptor sequencing (BCR-seq) profiles associated with CS, vaping, and dual-use. Methods: BCR-seq was performed on blood RNA samples from 234 participants in the COPDGene study. We assessed multivariable associations of B-cell function measures (immunoglobulin heavy chain (IGH) subclass expression and usage, class-switching, V allele usage, and clonal expansion) with CS, vaping, and dual-use. We adjusted for multiple comparisons using the Benjamini-Hochberg method, identifying significant associations at 5% FDR and suggestive associations at 10% FDR. Results: Among 234 non-Hispanic white (NHW) and African American (AA) participants, CS and dual-use were significantly positively associated with increased secretory IgA production, with dual-use showing the strongest associations. Dual-use was positively associated with class switching and B-cell clonal expansion, indicating increased B-cell activation, with similar trends in those only smoking or only vaping. The IGHV5-51*01 allele was increased in dual users. Conclusions: CS and vaping additively enhance B-cell activation, most notably in dual-users. CS and vaping are significantly associated to multiple alterations in B-cell function including increased class switching, clonal expansion, and a shift towards IgA-producing cell populations. These changes could be relevant to response to infection and vaccinations and merit further study.
KW - B cell
KW - COPD
KW - immune repertoire
KW - smoking
KW - vaping
UR - https://www.scopus.com/pages/publications/105005268757
UR - https://www.scopus.com/inward/citedby.url?scp=105005268757&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2025.1508786
DO - 10.3389/fimmu.2025.1508786
M3 - Article
C2 - 40386772
AN - SCOPUS:105005268757
SN - 1664-3224
VL - 16
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1508786
ER -